Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”

Ähnliche Einträge

• Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
  von: Emily R. Hankosky, et al.
  Veröffentlicht: (2025)
• Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
  von: Alpana P. Shukla, et al.
  Veröffentlicht: (2025)
• Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
  von: Hendra Zufry, et al.
  Veröffentlicht: (2025)
• Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
  von: Shanshan Hu, et al.
  Veröffentlicht: (2024)
• Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide
  von: Caroline Swift, et al.
  Veröffentlicht: (2024)